Company Profile

Endsulin LLC
Profile last edited on: 10/31/19      CAGE: 6NMJ4      UEI: NKXSJANV91J3

Business Identifier: Use on gene therapy in treatment of diabetes
Year Founded
2004
First Award
2018
Latest Award
2018
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1206 Sherman Avenue
Madison, WI 53703
   (608) 712-8207
   N/A
   www.endsulin.com
Location: Single
Congr. District: 02
County: Dane

Public Profile

Involving players with longtime experience in the field, Endsulin is researching the use of gene therapy as a treatment for Type 1 diabetes. The concept and the work underway builds on research that found a single DNA sequence responsible for promoting and activating the human insulin gene. The effort is to produce a single one-time injection which could provide diabetics with better control over their glucose levels and, by extension, improve their health.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 1 NIH $291,539
Project Title: Gene Therapy for Type 1 Diabetes

Key People / Management

  Hans W Sollinger

Company News

There are no news available.